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Abstract
Objectives: To assess the independent impact of new genetic variants on conversion to advanced stages of AMD,
controlling for established risk factors, and to determine the contribution of genes in predictive models.
Methods: In this prospective longitudinal study of 2765 individuals, 777 subjects progressed to neovascular disease (NV) or
geographic atrophy (GA) in either eye over 12 years. Recently reported genetic loci were assessed for their independent
effects on incident advanced AMD after controlling for 6 established loci in 5 genes, and demographic, behavioral, and
macular characteristics. New variants which remained significantly related to progression were then added to a final
multivariate model to assess their independent effects. The contribution of genes to risk models was assessed using
reclassification tables by determining risk within cross-classified quintiles for alternative models.
Results: Three new genetic variants were significantly related to progression: rare variant R1210C in CFH (hazard ratio (HR)
2.5, 95% confidence interval [CI] 1.2–5.3, P=0.01), and common variants in genes COL8A1 (HR 2.0, 95% CI 1.1–3.5, P=0.02)
and RAD51B (HR 0.8, 95% CI 0.60–0.97, P=0.03). The area under the curve statistic (AUC) was significantly higher for the 9
gene model (.884) vs the 0 gene model (.873), P=.01. AUC’s for the 9 vs 6 gene models were not significantly different, but
reclassification analyses indicated significant added information for more genes, with adjusted odds ratios (OR) for
progression within 5 years per one quintile increase in risk score of 2.7, P,0.001 for the 9 vs 6 loci model, and OR 3.5,
P,0.001 for the 9 vs. 0 gene model. Similar results were seen for NV and GA.
Conclusions: Rare variant CFH R1210C and common variants in COL8A1 and RAD51B plus six genes in previous models
contribute additional predictive information for advanced AMD beyond macular and behavioral phenotypes.
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Introduction
There is a strong genetic component and an important
environmental influence on the development of age-related
macular degeneration (AMD) [1,2]. Common loci in genes in
the complement and lipid pathways have been confirmed in
several studies. Since 2011, associations with AMD have been
shown for a novel rare variant (R1210C) in CFH [3] common
variants in COL10A1[4–6], COL8A1[4–6], VEGFA [5], and
TNFRSF10A [6,7] Additional common variants were also identi-
fied in our international consortium effort based on meta-analyses
of several genome-wide case-control association studies. [6] All of
these recently reported genes have been shown to be related to
advanced AMD when compared with controls. However, the
relative impact of most of these new genes on AMD progression
has not been reported, and their independent effects, while
controlling for all established genetic and non-genetic risk factors
for progression, are unknown.
In this study we, therefore, determined: 1) the independent
effect of each new genetic locus on AMD progression after
controlling for the known genetic, demographic, behavioral and
ocular risk factors related to progression, when each new locus was
considered separately, 2) whether the new genetic loci related to
AMD progression based on this initial analyses remained
significant predictors of progression when combined with variables
in our previous risk models, and 3) if genes and number of genes
significantly add to risk models for AMD progression.
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e87047Methods
The Age-Related Eye Disease Study included a randomized
clinical trial to assess the effect of antioxidant and mineral
supplements on risk of AMD and cataract and a longitudinal study
of AMD that ended in December 2005 [8] Research adhered to
the tenets of the Declaration of Helsinki. The research protocol
was approved by institutional review boards and all participants
signed consent statements. Follow-up time ranged from 0.5 to 13.0
years (mean 8.8 years). Phenotype data were accessed through the
Database of Genotypes and Phenotypes (dbGaP). Participants
were classified using the Clinical Age-Related Maculopathy
Staging System (CARMS) [9], based on ocular examination and
grading of fundus photographs at baseline, into 5 stages: normal or
stage 1 in both eyes (essentially free of age-related macular
abnormalities or a few small drusen), early AMD or stage 2 in the
worse eye (mild changes including multiple small drusen,
nonextensive intermediate drusen, and/or pigment abnormalities),
Table 1. Multivariate Associations between Baseline Demographic, Environmental, Macular Variables and Incidence of Advanced
AMD.
Progressors Non-progressors HR 95% CI* p - value
Total patients: (N=777) (N=1988)
Age (years) N (%) N (%)
,65 197 (25) 242 (12) 1.0 ref
65–74 476 (61) 1322 (66) 0.7 (0.6–0.9) 0.0007
55–64 104 (13) 424 (21) 0.6 (0.5–0.7) ,0.0001
Sex
Female 425 (55) 1135 (57) 1.0 ref
Male 352 (45) 853 (43) 1.1 (0.9–1.2) 0.42
Education
# High School 309 (40) 624 (31) 1.0 ref
. High School 468 (60) 1364 (69) 0.9 (0.8–1.0) 0.07
Smoking
Never 300 (39) 1008 (51) 1.0 ref
Past 410 (53) 880 (44) 1.1 (1.0–1.3) 0.09
Current 67 (9) 100 (5) 1.9 (1.4–2.4) ,0.0001
BMI
,25 227 (29) 672 (34) 1.0 ref
25–29 328 (42) 848 (43) 1.1 (0.9–1.3) 0.52
30+ 222 (29) 468 (24) 1.2 (1.0–1.5) 0.05
Advanced AMD in One Eye at Baseline
Neither Eye 522 (67) 1833 (92) 1.0 ref
Grade 4 49 (6) 6 (0.3) 7.1 (2.6–18.9) ,0.0001
Grade 5 206 (27) 149 (7) 5.0 (1.9–12.6) 0.0008
Individuals with Advanced AMD in One Eye at Baseline: Largest Drusen Size in Non-advanced Eye (microns)
,63 6 (2) 46 (30) 1.0 ref
63–124 41 (16) 57 (37) 4.4 (1.9–10.4) 0.0007
125–249 86 (34) 37 (24) 9.6 (4.2–22.0) ,0.0001
$250 122 (48) 15 (10) 16.6 (7.3–37.8) ,0.0001
Individuals Without Advanced AMD at Baseline: Size of Drusen (microns) in Each Eye
,63, ,63 17 (3) 807 (44) 1.0 ref
63–124, ,63 27 (5) 388 (21) 3.2 (1.8–6.0) 0.0002
63–124, 63–124 35 (7) 171 (9) 8.4 (4.7–15.1) ,0.0001
125–249, ,63 21 (4) 127 (7) 7.3 (3.8–13.9) ,0.0001
125–249, 63–124 64 (12) 155 (9) 15.3 (8.9–26.3) ,0.0001
125–249, 125–249 88 (17) 93 (5) 30.1 (18.2–52.0) ,0.0001
$250, #124 24 (5) 25 (1) 29.6 (15.8–55.4) ,0.0001
$250, 125–249 92 (18) 41 (2) 49.7 (29.4–84.1) ,0.0001
$250, $250 154 (30) 26 (1) 75.0 (45.2–124.5) ,0.0001
HR=hazard ratio; CI=confidence interval.
*Controlling for all variables in the table.
doi:10.1371/journal.pone.0087047.t001
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microns or greater diameter, extensive intermediate drusen), stage
4 in one eye (advanced dry AMD with central or non-central
geographic atrophy (GA), and stage 5 with advanced neovascular
(NV) AMD in one eye at baseline. Both cohorts were classified
using this system. Since category 3 patients in the original AREDS
classification included non-central geographic atrophy and cate-
gory 4 included both advanced forms of AMD as well as visual
loss regardless of phenotype [8], we reclassified these groups
independent of visual acuity level into CARMS grades 4 (GA) and
5 (NV) as described above.
Maximum drusen size within the grid (a 3000 micron radius
centered on the fovea) at baseline was used to assess drusen
phenotypes for eyes without advanced AMD. Drusen size was
based on standard circles with diameters corresponding to 63 mm,
125 mm, and 250 mm. Drusen size was divided into the following
categories: ,63 mm, 63–124 mm, 125–249 mm, and $250 mm.
AMD status and drusen size in eyes without AMD at baseline were
evaluated.
Table 2. Distribution of Age-Related Macular Degeneration Genetic Variants Among Progressors and Non-Progressors.
Gene/Genotype Progression Gene/Genotype Progression
Yes No p-value* Yes No p-value*
Total patients N (%) 777 (28.1) 1988 (71.9) 777 (28.1) 1988 (71.9)
CFH(Y402H) TT 123 (16) 723 (36) ,0.0001 LIPC CC 420 (54) 1036 (52) 0.25
CT 343 (44) 922 (46) CT 308 (40) 805 (40)
CC 311 (40) 343 (17) TT 49 (6) 147 (7)
CFH TT 29 (4) 329 (17) ,0.0001 ABCA1 CC 443 (57) 1094 (55) 0.28
CT 231 (30) 903 (45) CT 290 (37) 765 (38)
CC 517 (66) 756 (38) TT 44 (6) 129 (6)
ARMS2/HTRA1(A69S) GG 244 (31) 1164 (59) ,0.0001 FRK/COL10A1 CC 401 (52) 1046 (53) 0.73
GT 368 (47) 701 (35) CT 315 (41) 784 (40)
TT 165 (21) 123 (6) TT 60 (8) 155 (8)
C2 (E318D) GG 748 (96) 1827 (92) ,0.0001 APOC1/APOE AA 568 (73) 1422 (72) 0.41
CG/CC 29 (4) 161 (8) AG/GG 209 (27) 566 (28)
CFB (R32Q) CC 715 (93) 1615 (84) ,0.0001 TIMP3 AA 712 (92) 1774 (89) 0.06
CT/TT 56 (7) 318 (16) AC/CC 65 (8) 214 (11)
C3 (R102G) CC 386 (50) 1234 (62) ,0.0001 TNFRSF10A TT 222 (29) 540 (27) 0.87
CG 318 (41) 669 (34) GT 373 (48) 1020 (51)
GG 73 (9) 84 (4) GG 182 (23) 428 (22)
CFI CC 181 (23) 526 (26) 0.01 ADAMTS9/AS2** CC 241 (31) 581 (29) 0.27
CT 373 (48) 983 (50) CT 375 (48) 964 (48)
TT 223 (29) 479 (24) TT 161 (21) 443 (22)
CETP CC 310 (40) 880 (44) 0.003 SLC16A8 CC 493 (64) 1267 (64) 0.46
AC 356 (46) 902 (45) CT 241 (31) 641 (32)
AA 111 (14) 205 (10) TT 43 (6) 80 (4)
COL8A1 TT 594 (76) 1636 (82) 0.0004 DDR1 CC 546 (70) 1394 (70) 0.59
CT 170 (22) 332 (17) CT 218 (28) 540 (27)
CC 13 (2) 20 (1) TT 13 (2) 54 (3)
COL10A1 AA 292 (38) 715 (36) 0.06 TGFBR1 TT 463 (60) 1137 (57) 0.20
AG 379 (49) 921 (46) GT 271 (35) 722 (36)
GG 106 (14) 351 (18) GG 43 (6) 129 (6)
CFH R1210C CC 769 (99) 1982 (99.7) 0.02 VEGFA CC 150 (19) 451 (23) 0.06
CT 8 (1) 6 (0.3) CT 399 (51) 996 (50)
RAD51B AA 331 (43) 791 (40) 0.02 TT 228 (29) 540 (27)
AG 367 (47) 914 (46) HSPH1/B3GALTL TT 232 (30) 666 (34) 0.006
GG 79 (10) 283 (14) CT 369 (47) 963 (48)
HSPH1/B3GALTL TT 232 (30) 666 (34) 0.006 CC 176 (23) 359 (18)
CT 369 (47) 963 (48)
CC 176 (23) 359 (18)
*Mantel-Haenszel Chi-Square.
**ADAMTS9/ADAMTS9-AS2.
doi:10.1371/journal.pone.0087047.t002
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2 or 3 to either stage 4 or stage 5 at any follow-up visit to the end
of the study within each individual. In a subgroup analysis we
classified progressors to each advanced stage of AMD separately as
progression to GA and progression to NV. Time to progression
was recorded for the first eye to progress if both eyes were at risk,
and for the fellow eye if one eye was at risk. Individuals were
considered progressors if a) there was no advanced AMD in either
eye at baseline and they developed advanced AMD in at least one
eye during follow-up, or b) they had advanced AMD in one eye at
baseline and progressed to advanced AMD in the fellow eye
during follow-up. For subjects in group ‘‘a’’ above, we controlled
for baseline grade in each eye and evaluated the time to
progression in each eye and used the earlier of the two progression
times if both eyes progressed at different times. For subjects in
group ‘‘b’’ above, we controlled for AMD category in the affected
eye at baseline (i.e., CARMS grades 4 and 5), AMD grade in the
non-advanced eye at baseline, and evaluated the time to progress
in the fellow eye. Demographic and risk factor data, including
education, smoking history, and body mass index (BMI), were
obtained at the baseline visit from questionnaires and height and
weight measurements.
Table 3. Associations between New Age-Related Macular Degeneration Genetic Loci and Incidence of Advanced Age-Related
Macular Degeneration, Controlling for Demographic, Environmental, Ocular and Genetic Factors.
Gene: SNP (Reference Genotype)/Genotype Model A* Model B
`
HR 95% CI p-value p-trend HR 95% CI p-value p-trend
CFI:rs10033900 (CC) CT 1.0 (0.9–1.2) 0.78 1.1 (0.9–1.3) 0.45
TT 1.1 (0.9–1.3) 0.48 0.47 1.1 (0.9–1.3) 0.38 0.39
LIPC:rs10468017 (CC) CT 1.1(0.9–1.2) 0.51 1.0 (0.9–1.2) 0.65
TT 1.1(0.8–1.3) 0.42 0.35 1.1 (0.8–1.5) 0.40 0.41
CETP: rs3764261 (CC) AC 1.1 (0.9–1.2) 0.48 1.0 (0.9–1.2) 0.56
AA 1.1 (0.9–1.4) 0.29 0.27 1.2 (0.9–1.4) 0.19 0.21
ABCA1: rs1883025 (CC) CT 1.1 (0.9–1.2) 0.46 1.1 (0.9–1.2) 0.35
TT 1.0 (0.7–1.3) 0.75 0.78 0.9 (0.6–1.2) 0.32 0.95
TIMP3: rs9621532 (AA) AC/CC 0.8 (0.6–1.0) 0.07 – 0.8 (0.6–1.0) 0.11 -
COL8A1:rs13095226 (TT) CT 1.2 (1.0–1.4) 0.09 1.1 (0.9–1.3) 0.21
CC 1.9 (1.1–3.3) 0.02 0.02 1.9 (1.1–3.3) 0.02 0.04
FRK/COL10A1: rs1999930 (CC) CT 1.1 (0.9–1.2) 0.45 1.0 (0.9–1.2) 0.93
TT 1.0 (0.7–1.3) 0.83 0.78 0.9 (0.7–1.2) 0.71 0.83
COL10A1: rs1064583 (AA) AG 1.1 (0.9–1.3) 0.29 1.1 (0.9–1.3) 0.35
GG 0.8 (0.7–1.0) 0.13 0.36 0.8 (0.7–1.0) 0.10 0.28
VEGFA: rs943080 (CC) CT 1.1 (0.9–1.3) 0.30 1.1 (0.9–1.3) 0.38
TT 1.0 (0.8–1.2) 0.72 0.54 1.0 (0.8–1.2) 0.96 0.82
TNFRSF10A: rs13278062 (TT) GT 1.0 (0.8–1.2) 0.91 1.0 (0.8–1.2) 0.74
GG 1.2 (1.0–1.4) 0.11 0.14 1.1 (0.9–1.4) 0.22 0.27
CFH R1210C:rs121913059 (CC) CT 1.4 (0.7–2.9) 0.31 – 2.4 (1.2–4.9) 0.02 –
APOC1/APOE: rs4420638 (AA) AG/GG 1.0 (0.9–1.2) 0.80 – 1.0 (0.8–1.2) 0.94 –
DDR1:rs3094111 (CC) CT 1.1 (0.9–1.3) 0.40 1.1 (0.9–1.3) 0.31
TT 0.9 (0.5–1.6) 0.82 0.54 1.1 (0.6–1.9) 0.77 0.32
SLC16A8: rs8135665 (CC) CT 1.0 (0.9–1.2) 0.58 1.1 (0.9–1.2) 0.51
TT 1.2 (0.9–1.7) 0.23 0.25 1.2 (0.9–1.6) 0.29 0.27
TGFBR1: rs334353 (TT) GT 1.0 (0.9–1.2) 0.85 1.0 (0.9–1.2) 0.98
GG 1.0 (0.8–1.4) 0.86 0.81 1.0 (0.7–1.4) 0.93 0.94
RAD51B: rs8017304 (AA) AG 0.9 (0.7–0.99) 0.04 0.9 (0.7–0.99) 0.04
GG 0.7 (0.6–0.96) 0.02 0.007 0.8 (0.6–0.98) 0.04 0.01
ADAMTS9/AS2**: rs6795735 (CC) CT 1.0 (0.8–1.1) 0.89 1.0 (0.8–1.1) 0.73
TT 0.9 (0.8–1.3) 0.51 0.70 0.9 (0.8–1.1) 0.49 0.83
HSPH1/B3GALTL: rs9542236 (TT) CT 1.2 (1.0–1.4) 0.03 1.1 (1.0–1.3) 0.17
CC 1.2 (1.0–1.5) 0.06 0.04 1.1 (0.9–1.3) 0.40 0.33
*Model A=Controlling for: age, gender, education, body mass index, smoking, 4 treatment groups,
baseline macular grade and drusen status.
`Model B=Controlling for: age, gender, education, body mass index, smoking, 4 treatment groups,
baseline macular grade, drusen status, CFHrs1410996, CFH Y402H, ARMS2/HTRA1, C3, C2 and CFB.
**ADAMTS9/ADAMTS9-AS2.
doi:10.1371/journal.pone.0087047.t003
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Common single nucleotide polymorphisms (SNPs) associated
with AMD were evaluated 1) Complement Factor H (CFH)
Y402H (rs1061170) [10], 2) CFH rs1410996, an independently
associated single nucleotide polymorphism (SNP) variant within
intron 14 of CFH [11], 3) ARMS2/HTRA1 (rs10490924) [12–14],
4) Complement component 2 or C2 E318D (rs9332739) [11,15], 5)
Complement Factor B or CFB R32Q (rs641153) [11,15], 6)
Complement component 3 or C3 R102G (rs2230199) [16,17], 7)
complement factor I, or CFI (rs10033900), an independently
associated SNP located in the linkage peak region of chromosome
4, 2781 base pairs upstream of the 39 untranslated region of CFI
[18], and 8) hepatic lipase C, or LIPC (rs10468017), a promoter
variant on chromosome 15q22 [4], 9) Cholesteryl ester transfer
protein, or CETP (rs3764261) [4,19], 10) ATP-binding cassette
subfamily A member 1, or ABCA1 (rs1883025) [4,19] 11) TIMP
metalloproteinase inhibitor 3, or TIMP3 (rs9621532) [4,19], 12)
Collagen type VIII, alpha1 or COL8A1(rs13095226) [4,5], 13)
FRK/COL10A1 rs199930 [4,5], 14) Collagen, type X, alpha 1 or
COL10A1 (rs1064583) [5,6], 15) Vascular endothelial growth
factor A, or VEGFA (rs943080) [5], 16) Tumor necrosis factor
receptor superfamily, member 10a or TNFRSF10A (rs13278062
[6,7], 17) Apolipoprotein E and Apolipoprotein C- I or APOE/
APOC1 rs4420638 [6,20,21], 18) Discodin domain receptor
tyrosine kinase 1, or DDR1 (rs3094111) [6], 19) Solute carrier
family 16, member 8 (monocarboxylic acid transporter 3or
SLC16A8 (rs8135665) [6], 20) Transforming growth factor, beta
receptor 1 or TGFBR1 (rs334353) [6], 21) RAD51 homolog B (S.
cerevisiae) or RAD51B (rs8017304) [6], 22) ADAM metallopepti-
dase with thrombospondin type 1 motif [6]; ADAMTS9 antisense
RNA 2 (non-protein coding) or ADAMTS9/ADAMTS9-AS2
(rs6795735) [6] 23) Beta 1,3- galactosyltransferase -like or
B3GALTL (rs9542236) [6]. The rare variant in CFH, R1210C
rs121913059 was also evaluated [3].
Statistical Analyses
Analyses were performed using the Cox proportional hazards
model to evaluate relationships between progression of AMD and
the following variables: genotypes, age (,65, 65–74, 75+), gender,
education (high school or less, more than high school), cigarette
smoking (never, past, current), and BMI, which was calculated as
the weight in kilograms divided by the square of the height in
meters (,25, 25–29.9, and 30+), baseline stage of AMD and
drusen characteristics in both eyes. Hazard ratios (HRs) and 95%
confidence intervals (CI) were calculated for demographic,
behavioral, ocular and genetic factors. The method for calculating
Table 4. Multivariate Associations Between Genes and Progression to Advanced Age-Related Macular Degeneration.
Gene: SNP/Genotype 6 Gene Model* 9 Gene Model
`
HR 95% CI p-value p-trend HR 95% CI p-value p-trend
CFH:rs1061170 (Y402H) TT 1.0 (ref.) 1.0 (ref.)
CT 1.1 (0.9–1.3) 0.63 1.1 (0.9–1.4) 0.40
CC 1.2 (0.9–1.5) 0.31 0.29 1.2 (0.9–1.5) 0.25 0.26
CFH:rs1410996 TT 1.0 (ref.) 1.0 (ref.)
CT 2.0 (1.3–3.0) 0.002 1.9 (1.2–2.9) 0.004
CC 2.4 (1.6–3.8) ,0.0001 0.0002 2.4 (1.5–3.7) 0.0001 0.0001
ARMS2/HTRA1:rs10490924(A69S) GG 1.0 (ref.) 1.0 (ref.)
GT 1.3 (1.1–1.6) 0.001 1.3 (1.1–1.6) 0.0008
TT 1.8 (1.5–2.3) ,0.0001 ,0.0001 1.9 (1.5–2.3) ,0.0001 ,0.0001
C2:rs9332739(E318D) GG 1.0 (ref.) 1.0 (ref.)
CG/CC 0.7 (0.5–1.0) 0.05 – 0.7 (0.5–1.0) 0.06 –
CFB:rs641153(R32Q) CC 1.0 (ref.) 1.0 (ref.)
CT/TT 0.7 (0.5–0.9) 0.004 – 0.7 (0.5–0.9) 0.006 –
C3:rs2230199(R102G) CC 1.0 (ref.) 1.0 (ref.)
CG 1.1 (1.0–1.3) 0.19 1.1 (1.0–1.3) 0.13
GG 1.4 (1.1–1.8) 0.01 0.01 1.4 (1.1–1.8) 0.009 0.006
COL8A1:rs13095226 TT – – 1.0 (ref.)
CT – – 1.1 (0.9–1.3) 0.21
CC – – 2.0 (1.1–3.5) 0.02 0.04
CFH R1210C:rs121913059 CC – – 1.0 (ref.)
CT – – 2.5 (1.2–5.3) 0.01 –
RAD51B: rs8017304 AA – – 1.0 (ref.)
AG – – 0.9 (0.7–1.0) 0.05
GG – – 0.8(0.6–0.97) 0.03 0.01
*6 Gene Model=Controlling for: age, gender, education, body mass index, smoking, baseline macular grade, drusen status, 4 treatment groups, CFH rs1410996,
CFHY402H, ARMS2/HTRA1, C2,C3 and CFB genes.
`9 Gene Model=Controlling for: age, gender, education, body mass index, smoking, baseline macular grade, drusen status, 4 treatment groups and all genes in the
table.
doi:10.1371/journal.pone.0087047.t004
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regression coefficients of all demographic, environmental, genetic
and ocular factors, has been reported previously [22–24].
Survival analysis was used to determine 5-year and 10-year
cumulative incidence rates of AMD and the advanced AMD
subtypes for individual subjects according to various risk factor
levels at baseline. To assess discrimination, the AUC (area under
the ROC, or receiver operating curve) was obtained for
progression within 5 years and progression within 10 years. In
addition, an age-adjusted concordance or ‘‘C’’ statistic based on
Table 5. 9 Gene Model for Geographic Atrophy and Neovascular Disease.
Gene: SNP/Genotype Geographic Atrophy (N=416)** Neovascular Disease (N=527)**
HR 95% CI* p-value p-trend HR 95% CI* p-value p-trend
CFH:rs1061170 (Y402H) TT 1.0 (ref) 1.0 (ref)
CT 1.08(0.78–1.5) 0.63 1.31(0.97–1.76) 0.08
CC 1.27(0.87–1.84) 0.22 0.19 1.26(0.9–1.76) 0.17 0.33
CFH:rs1410996 TT 1.0 (ref) 1.0 (ref)
CT 1.52(0.89–2.6) 0.13 1.77(1.01–3.1) 0.047
CC 1.69(0.96–2.99) 0.07 0.11 2.45(1.37–4.38) 0.002 ,0.001
ARMS2/HTRA1:rs10490924(A69S) GG 1.0 (ref) 1.0 (ref)
GT 1.39(1.1–1.75) 0.005 1.43(1.16–1.76) ,0.001
TT 1.74(1.3–2.32) ,0.001 ,0.001 1.94(1.5–2.49) ,0.0001 ,0.0001
C2:rs9332739(E318D) GG 1.0 (ref) 1.0 (ref)
CG/CC 0.61(0.33–1.11) 0.11 0.10 0.78(0.5–1.21) 0.26 0.21
CFB:rs641153(R32Q) CC 1.0 (ref) 1.0 (ref)
CT/TT 0.68(0.46–1.0) 0.050 0.06 0.62(0.44–0.88) 0.008 0.009
C3:rs2230199(R102G) CC 1.0 (ref) 1.0 (ref)
CG 1.1(0.89–1.35) 0.39 1.13(0.94–1.36) 0.20
GG 1.26(0.87–1.83) 0.23 0.16 1.42(1.05–1.93) 0.026 0.021
COL8A1:rs13095226 TT 1.0 (ref) 1.0 (ref)
CT 1.05(0.83–1.34) 0.67 1.27(1.03–1.56) 0.025
CC 2.02(0.99–4.15) 0.055 0.24 1.61(0.79–3.24) 0.19 0.016
CFH R1210C:rs121913059 CC 1.0 (ref) 1.0 (ref)
CT 3.12(1.33–7.29) 0.009 0.006 3.09(1.33–7.19) 0.008 0.001
RAD51B: rs8017304 AA 1.0 (ref) 1.0 (ref)
AG 0.91(0.73–1.12) 0.36 0.90(0.76–1.08) 0.28
GG 0.96(0.68–1.34) 0.79 0.49 0.67(0.49–0.92) 0.013 0.016
*Controlling for: Age, gender, education, body mass index, smoking, baseline macular grade, drusen status, 4 treatment groups and all genes in the table.
**Some individuals progressed to Geographic Atrophy in one eye and Neovascular Disease in the fellow eye.
doi:10.1371/journal.pone.0087047.t005
Table 6. Area Under the Curve Statistics for Progression to Advanced Age-Related Macular Degeneration, Geographic Atrophy
and Neovascular Disease at 5 and 10 Years After Baseline.
AUC (SE) AUC (SE) AUC (SE) p-value p-value
0 Gene Model 6 Gene Model 9 Gene Model 6 vs 9 Gene Model 0 vs 9 Gene Model
5 Year
All advanced AMD 0.873 (0.009) 0.883 (0.008) 0.884 (0.008) 0.24 0.01
Geographic Atrophy 0.886 (0.012) 0.892 (0.012) 0.893 (0.012) 0.64 0.12
Neovascular Disease 0.860 (0.012) 0.875 (0.011) 0.876 (0.011) 0.30 0.02
10 Year
All advanced AMD 0.898 (0.007) 0.910 (0.006) 0.911 (0.006) 0.56 0.001
Geographic Atrophy 0.914 (0.009) 0.921 (0.008) 0.920 (0.008) 0.90 0.02
Neovascular Disease 0.879 (0.009) 0.896 (0.009) 0.897(0.009) 0.43 0.001
SE=Standard Error.
doi:10.1371/journal.pone.0087047.t006
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based on the group of risk factors in that model from a random
progressor was higher than the corresponding risk score from a
random non-progressor within the same 10-year age group [25].
Confidence limits were obtained and C statistics were compared
between competing models [26].
To assess the added value of a model with genes vs. models with
fewer or no genes, we calculated quintiles of risk score according to
each model and cross-classified the quintile of risk score derived
from one model by quintile of risk score derived from the other.
We then ran a logistic regression of progression within 5 years
(yes/no) on risk score quintile of the zero gene model (treated as a
categorical variable with regression coefficients b1, b2, b3, b4) and
the 9 gene model risk score quintile, expressed as an ordinal
variable with values 1 to 5 with regression coefficient c. The odds
ratio (OR) of progression to advanced AMD per one unit increase
in quintile of the 9 gene model risk score, holding the risk score
quintile of the zero gene model constant, was measured by exp (c).
A similar approach was used to assess the added value of the 9
gene model vs the 6 gene model.
Results
Among 2765 individuals, there were 777 progressors to
advanced stages of AMD in either eye, and 1988 non-progressors.
Among the progressors, 416 progressed to GA in at least one eye
and 527 progressed to NV in at least one eye. The mean ages (6
SD) of progressors and non-progressors at baseline were 70.2
(65.2) and 68.2 (64.7).
Table 1 displays the multivariate associations between baseline
demographic, environmental and macular variables and incident
advanced AMD. Increasing age, current smoking and higher BMI
were related to progression. Advanced AMD in one eye and larger
drusen size in the fellow eye, as well as larger drusen size in both
eyes among individuals without advanced AMD at baseline were
strongly related to higher rates of conversion from early and
intermediate to advanced stages of AMD.
The distributions of genetic variants among progressors and
non-progressors are shown in Table 2. There were significant and
positive associations between progression and the number of risk
alleles for CFH Y402H, CFH rs1410996, ARMS2/HTRA1 and C3.
In addition there were protective effects for the minor alleles of C2
and CFB. We found significant positive associations with risk
alleles for CFI, CETP, and HSPH1/B3GALTL, and a significant
protective association for the minor allele of RAD51B. Further-
more, there were borderline positive associations with VEGFA
(P=.06) and borderline protective associations for COL10A1 and
TIMP3 (P=.06). No significant associations with progression to
advanced AMD were found for LIPC, ABCA1, TNFRSF10A,
APOC1/APOE, DDR1, SLC16A8, TGFBR1, and ADAMTS9 in
these analyses.
Table 3 displays the multivariate associations between incident
AMD and the novel gene variants in two models: A) adjusted for
demographic, environmental and macular variables, and B)
controlling for the 6 genetic variants in 5 genes (referred to herein
Figure 1. Cross-Classification of Progression Rates to Advanced AMD: 9 Gene Model vs 6 Gene Model. Cross-classification of subjects by
risk score quintile for 9 and 6 gene models, with estimated progression rates for each combination of a 9 gene quintile by 6 gene quintile. OR=odds
ratio of progression per one quintile increase in 9 gene model, holding 6 gene model quintile constant.
doi:10.1371/journal.pone.0087047.g001
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Model A. In Model B, COL8A1 (CC vs TT, HR=1.9, P=.02, P
trend=0.04), CFH R1210C (HR 2.4, P=.02) and RAD51B (GG vs
AA, HR 0.80, P=.04, P trend=0.01), were significantly related to
AMD progression to advanced stages independent of the other
variables.
Table 4 shows two models: 1) the 6 gene model in our previous
prediction paper [22–24], with multivariate associations between
incident advanced AMD and the genetic variants adjusted for
demographic, environmental, and macular phenotypes, and 2) the
9 gene model (9 genetic loci in 7 genes, herein referred to as the ‘‘9
gene model’’) with the addition of the 3 significant genetic loci
identified in Table 3, mutually adjusted for each other as well as
the other 6 genetic loci. We found independent effects of the
variants in COL8A1 (CC vs TT, HR=2.0, P=.02, P trend=0.04),
CFH R1210C (CT vs CC, HR=2.5, P=.01), and RAD51B (GG vs
AA, HR=0.80, P=.03, P trend=0.01).
Table 5 depicts similar analyses for progression to GA and NV
separately. Associations with some genetic variants were somewhat
stronger for NV than GA, although HR’s were in the same
direction generally for both phenotypes, except for RAD51B which
was not related to GA.
In Table 6, we estimated the AUC’s corrected for age for gene
models predicting progression at 5 years and 10 years. For 5 year
progression, the AUC’s were as follows: 0 gene model 0.873, 6
gene model 0.883, 9 gene model 0.884; P=0.01 for 0 gene vs 9
gene model and P=0.24 for 9 gene vs 6 gene model. Similarly, for
10 year progression, AUC’s were 0.898, 0.910, and 0.911 for the
0, 6, and 9 gene models, respectively, with P=0.001 for the 9 vs 0
gene model comparison of the AUC’s but no significant difference
in AUC’s for the 9 vs 6 gene model. Changes in AUC’s for the 9
gene vs 0 gene models were somewhat larger for NV than GA for
both 5 and 10 year progression.
Previous studies in a variety of settings have revealed that the
AUC is a relatively insensitive statistic for identifying improvement
in model fit [27]. An alternative approach is provided by
reclassification models where risk is cross-classified simultaneously
for level of risk predicted by 2 different competing models. For this
purpose we cross-classified subjects by risk score derived from the
models and divided into quintiles (Q) and estimated rates of
progression for each combination of a 6 gene risk score quintile by
a 9 gene risk score quintile. The results are displayed in Figure 1.
Qualitatively it appears, especially for high risk individuals (risk
score Q4 and Q5), while holding the 6 gene model risk score
quintile constant, there is an increasing progression rate as the 9
gene risk score quintile increases. Little additional information is
provided for low risk individuals (Q1 and Q2). Overall, the OR
per risk score quintile increase in the 9 gene model controlling for
the 6 gene model risk score quintile was 2.7 (95% CI 1.7–4.4)
P,0.001, indicating that significant additional information
regarding progression is provided by the 9 gene model compared
to the 6 gene model.
Given the ongoing discussion of the value in adding genetic
information to predictive models, we also compared the model
with 9 genetic loci to the model without genes (0 gene model) as
shown in Figure 2. There are larger differences between the 9
Figure 2. Cross-Classification of Progression Rates to Advanced AMD: 9 Gene Model vs 0 Gene Model. Cross-classification of subjects by
risk score quintile for 9 and 0 gene models, with estimated progression rates for each combination of a 9 gene quintile by 0 gene quintile. OR=odds
ratio of progression per one quintile increase in 9 gene model, holding 0 gene model quintile constant.
doi:10.1371/journal.pone.0087047.g002
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models. There are large differences in progression rate as the 9
gene model risk score quintile increases, when holding the 0 gene
model risk score quintile constant, for the highest risk individuals
(i.e. Q4 and Q5 in the 0 gene model). For intermediate risk
individuals (Q2 and Q3) for the 0 gene model, there are also
discernible increases in progression rates as the 9 gene model risk
score quintile increases. However, little added value is apparent for
the lowest risk quintile (Q1) for the 9 gene loci vs 0 gene model.
The OR per quintile increase in the 9 gene model controlling for
the 0 gene model was 3.5 (95% CI 2.6–4.6), P,0.001, indicating
that significant additional information is obtained by including
genes in the predictive model.
In Figures 3 and 4, we depict the comparison of the 9 gene vs
0 gene models for progression at 5 years to GA and NV separately.
The major incremental precision obtained from including 9 genes
in the prediction model is obtained from subjects at high risk in the
0 gene model (i.e. Q4 and Q5), with smaller increments for
intermediate risk subjects (Q3) and little benefit for low risk
individuals (Q1 and Q2). The OR’s are 3.3, P,0.001 for GA
(Figure 3), and 3.1, P,0.001 for NV (Figure 4).
Discussion
To our knowledge this is the first report on the independent
associations between R1210C in CFH, COL8A1 and RAD51B and
progression to advanced AMD, controlling for all known AMD
genetic loci. The AUC’s for the 9 gene vs 0 gene models were
significantly different but were similar for the 9 and 6 gene models.
To further discriminate between the two models which included
genes, we used a re-classification approach, which is novel for
AMD risk models, but has been used in other settings [27]. Cross
classifying quintile of risk in the 9 gene by 6 gene models, holding
the 6 gene model constant, demonstrated an increased risk of
progression in the 4
th and 5
th quintiles of the risk score, indicating
that incorporating a larger number of independent AMD genetic
loci enhanced predictive power. Using a similar approach, larger
increases in predictive accuracy were apparent for the model with
9 genes compared to none.
Our first prediction models for advanced AMD beginning in
2006 included only genes [11], a model with environmental and
demographic variables only (AUC 0.62), and a model that
included CFHY402H genotype (AUC 0.74) [28]. These early
models demonstrated the importance of genetic variants in
predicting AMD risk. When ARMS2/HTRA1 was added to the
genetic model with CFHY402H along with demographic and
environmental factors, the AUC increased moderately to 0.78
[29]. The first multi-gene prediction model with 6 loci in 5 genes
in addition to demographic and environmental factors, increased
the C statistic to 0.83, adding to the evidence that genetic
susceptibility plays a large role in predicting AMD risk [22]. The
addition of macular phenotype and baseline AMD grade to the
genetic and environmental models increased the AUC to 0.89
[23]. Other prediction models include our Markov model of
Figure 3. Cross-Classification of Progression Rates to Geographic Atrophy: 9 Gene Model vs 0 Gene Model. Cross-classification of
subjects progressing to Geographic Atrophy by risk score quintile for 9 and 0 gene models, with estimated progression rates for each combination of
a 9 gene quintile by 0 gene quintile. OR=odds ratio of progression per one quintile increase in 9 gene model, holding 0 gene model quintile
constant.
doi:10.1371/journal.pone.0087047.g003
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complement levels in the model [30,31]. The Markov model
included CFH, ARMS2, C2, CFB, C3, CFI and genes in the
cholesterol and collagen pathways (LIPC, CETP, COL8A1)i n
addition to drusen phenotypes, demographic, and environmental
characteristics. The 5 year AUC in that model was 0.88 [30]. The
addition of complement plasma markers to a model in a case-
control study, together with 6 complement pathway loci, ARMS2/
HTRA1, demographic and environmental characteristics increased
the C-statistic to 0.94 [31].
AUC is a reasonable measure of discrimination for a risk
prediction rule and by definition is based on the relative order of
risk between progressors and non-progressors. However, it does
not take into account the magnitude of the differences in risk.
Thus, it does not provide all the information in determination of
risk. In populations dominated by low risk individuals, there are
ways to re-classify higher risk subjects to obtain a more accurate
risk profile. Cook et al. demonstrated this in the Women’s Health
Study population assessing cardiovascular risk in models with and
without hsCRP [27]. In that study, hsCRP had little effect on the
C-statistic. However, if one cross-classifies subjects by risk level
with and without hsCRP, individuals in the low and medium risk
groups (5–10% and 10–20% 10 year Framingham risk) were re-
classified (21% and 19% of the time, respectively) into different
risk groups [27]. Rosner et al. used a similar approach for cross-
classifying breast cancer risk scores with and without estradiol
[32]. Similar to the hsCRP study, the AUC did not increase
substantially with the addition of estradiol. However, when risk
deciles in the estradiol and non-estradiol models were cross-
classified, there was an estimated 67% increase in breast cancer
incidence for an increase of one decile of risk for the estradiol
model holding the non-estradiol model decile constant [32]. In our
study of macular degeneration, 5–10% of subjects were reclassified
into a different quintile for the 9 gene vs 6 gene models, and 15–
30% of subjects were reclassified for the 9 vs 0 gene models,
indicating an improvement in model accuracy with the addition of
genetic variants.
The mechanisms by which CFH R1210C, COL8A1, and
RAD51B genes are related to the development and progression
of advanced AMD are being explored. The R1210C mutation has
been shown to compromise portions of the complement cascade
resulting in defective binding to C3d, C3b, heparin and
endothelial cells [3]. The COL8A1 gene, encodes one of the two
alpha chains of type VIII collagen, a major component of the
multiple basement membranes in the eye, including Bruch’s
membrane and the choroidal stroma [4,33]. The protein encoded
by RAD51B is a member of the RAD51 protein family, and is
essential for DNA repair mechanisms. This gene is also involved in
cell cycle delay and apoptosis [34].
Conclusions
We have presented a model with 9 common and rare predictive
genetic loci for progression to advanced stages of AMD that adds
Figure 4. Cross-Classification of Progression Rates to Neovascular Disease: 9 Gene Model vs 0 Gene Model. Cross-classification of
subjects progressing to Neovascular Disease by risk score quintile for 9 and 0 gene models, with estimated progression rates for each combination of
a 9 gene quintile by 0 gene quintile. OR=odds ratio of progression per one quintile increase in 9 gene model, holding 0 gene model quintile
constant.
doi:10.1371/journal.pone.0087047.g004
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loci or a model without any genetic information. New rare and
highly penetrant loci in addition to the rare variant CFH R1210C
[3,35] and several common loci included here, may further
improve the accuracy of AMD risk models. Our models can be
used for clinical research such as selecting individuals at high risk
for increased surveillance and for inclusion in clinical trials of new
therapies [23], and for assessing different responses to AMD
treatments based on the risk score.
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